SCHEMBL3500539

SCHEMBL3500539

CCOC(=O)c1cc2ccc(-c3ccc(Cl)cc3)cc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
PTPN2 P17706 2/20 0.46
ALPL P05186 1/20 0.45
TARBP2 Q15633 1/20 0.45
PTPN11 Q06124 2/20 0.45
GAA P10253 1/20 0.44
PRKCZ Q05513 2/20 0.44
ALOX15 P16050 1/20 0.44
GABRA2 P47869 3/20 0.43
GABRB2 P47870 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GCGR P47871 1/20 0.43
PKM P14618 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
SIRT3 Q9NTG7 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498021 0.90 MAPT (0.50) MAPTTRPM8PTPN2ALPLTARBP2
SCHEMBL16595447 0.89 ALOX15 (0.51) MAPTTRPM8PTPN2GAAALOX15
SCHEMBL29559740 0.89 ALOX15 (0.51) MAPTTRPM8PTPN2GAAALOX15
SCHEMBL3499141 0.85 HDAC1 (0.51) MAPTPTPN2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL18264030 0.81 PTPN2 (0.49) MAPTTRPM8PTPN2GAAALOX15
SCHEMBL8250276 0.80 HDAC1 (0.60) MAPTTRPM8PTPN2GAAALDH1A1
SCHEMBL1390384 0.79 HSD17B1 (0.51) MAPTPTPN2GAAALDH1A1KDM4E
SCHEMBL31207824 0.79 HSD17B1 (0.51) MAPTPTPN2GAAALDH1A1KDM4E
SCHEMBL155423 0.79 PTPN2 (0.50) MAPTPTPN2GAAGABRB2ALDH1A1
SCHEMBL3498337 0.79 RPA1 (0.55) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MAPT 4820/4885TRPM8 216/4885PTPN2 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.